CN Patent

CN113966334B — 化合物(i)的晶体形式

Assigned to Cable Chart Pharmaceutical Co · Expires 2025-01-21 · 1y expired

What this patent protects

公开了化合物(I)的晶形：其药学上可接受的盐以及任何前述物质的溶剂化物。还公开了包含它们的药物组合物、使用它们治疗与致癌KIT和PDGFRA改变相关的病症和病状的方法，以及制备化合物(I)及其晶形的方法。

USPTO Abstract

公开了化合物(I)的晶形：其药学上可接受的盐以及任何前述物质的溶剂化物。还公开了包含它们的药物组合物、使用它们治疗与致癌KIT和PDGFRA改变相关的病症和病状的方法，以及制备化合物(I)及其晶形的方法。

Drugs covered by this patent

Ayvakit (AVAPRITINIB) · Blueprint Medicines

Patent Metadata

Patent number: CN113966334B
Jurisdiction: CN
Classification: —
Expires: 2025-01-21
Drug substance claim: No
Drug product claim: No
Assignee: Cable Chart Pharmaceutical Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.